I was recently diagnosed with anti-NMDA receptor encephalitis
A software developer’s account of being diagnosed with anti-NMDA receptor encephalitis prompts reflections on how easily rare autoimmune brain diseases can be mistaken for primary psychiatric disorders. Commenters highlight the limits and biases of current medical practice, the life-or-death importance of patient advocates and access to specialists, and the promise and pitfalls of tools like AI in navigating complex or misdiagnosed conditions. Many also express gratitude for modern immunotherapies and call for greater awareness, research, and more accessible biomedical innovation.
Overall reaction & support
- Many express empathy, relief at the good prognosis, and gratitude for the write‑up and prior open‑source work.
- Several note how eye‑opening it is that such severe, surreal symptoms can come from a treatable, relatively new diagnosis.
Misdiagnosis, psychiatry, and the healthcare system
- Multiple stories describe serious conditions (autoimmune disease, diabetes, spinal injury, gallbladder rupture, encephalitis, lupus, etc.) initially dismissed as anxiety, “in your head,” or minor issues.
- Commenters highlight how a prior psychiatric label can anchor later clinicians toward psych explanations and away from neurology.
- Some clinicians in the thread acknowledge time pressure, cognitive bias, and the difficulty of recognizing rare “zebras” among many benign complaints.
- Others emphasize systemic issues: short visit times, fragmented records, SES and gender biases, and the need for a strong patient advocate or “wingman.”
Autoimmune and rare disorders
- Many share experiences with autoimmune or rare conditions: anti-NMDA encephalitis variants, MCAS, EGPA, LADA, ME/CFS, long‑COVID, paraneoplastic syndromes, etc.
- Common themes: years of misdiagnosis, vague multisystem symptoms, overlapping psychiatric features, and partial or delayed recovery.
- Some note associated tumors or idiopathic cases; others mention coexisting autoimmune diseases and family history.
Imaging, diagnostics, and AI tools
- Several argue for aggressive imaging (e.g., MRI) for unexplained neuro/psych symptoms; others caution about overtesting and finite resources.
- There is strong interest in better diagnostic technology (including AI “tricorder‑like” tools) to reduce human bias.
- Some report LLMs helping them or relatives converge on likely diagnoses (e.g., withdrawal syndromes, MCAS, POTS, EDS) and treatment trials; others report AI being unhelpful or confusing.
- Consensus: AI is valuable as a second opinion and research assistant, but not a replacement for clinicians.
Research, treatment, and biomedical progress
- Commenters stress that anti‑NMDA receptor encephalitis was only characterized in 2007, illustrating how new entities can reframe what was once “just schizophrenia.”
- There is praise for IVIG/monoclonal antibody therapies and rapid vaccine development as under‑appreciated biomedical successes.
- Some call for a “tech‑like boom” in biomedicine, while others note constraints from regulation, clinical trial realities, and the inherent complexity of biology.
Mortality, fragility, and life changes
- Statistical back‑of‑the‑envelope calculations about HN reader mortality spur reflection on how fragile health is.
- Several mention that severe illness reshapes priorities, relationships, and appreciation for everyday life.